Agilent customers are finding new ways to treat cancer, ensure food, water, air, and medicine quality and safety, discover new drug treatments, research infectious diseases, and create alternative energy solutions for a greener planet. From start to finish, we have them covered with our vast product solutions and services portfolio.
Around the world, Agilent’s people bring innovations, technologies, and services to the forefront of science. Our teams design and manufacture a wide array of advanced analytical, research, and diagnostic solutions and tools for use inside and outside laboratories.
Additionally, the unique expertise of Agilent’s CrossLab and technical teams provides valuable insight and support to our customers, helping them fully optimize their laboratories and resources to better focus on what's important: bringing great science to life.
In fiscal 2022, Agilent Technologies generated revenue of (US) $6.85 billion.
Time is the most critical facet in the laboratory today: time to get life-saving therapies to patients faster; reclaiming time by automating tedious manual workflows; and saving time otherwise spent addressing erroneous or complex results.
At Beckman Coulter Life Sciences, we are partners in time. We accelerate answers to critical questions through the power of efficiency, saving hours from some workflows and delivering reliable outcomes in liquid handling, genomics, flow cytometry, particle analysis/counting, and centrifugation.
We develop innovations for scientists by scientists, with many of our 3,300+ global colleagues coming from the laboratory with a deep understanding of today’s challenges and complexities. We’re passionate about translating science in partnership with our customers, and our customizable, accessible and sustainable solutions empower them with intuitive workflow efficiencies.
Time and again customers put their trust in us, with 400,000+ of our built-to-last products currently delivering results in labs worldwide – all backed by our dependable service and application experts offering educational insights and tailored support.
It’s all part of our time-tested approach since 1935 to bring meaningful innovations at the speed of life—and we’re just beginning. Working together, let’s advance human health for a better tomorrow!
FOR U.S. SERVICE SUPPORT, please call 800-369-0333 or email csdservice@beckman.com
Privacy Policy: https://www.beckman.com/about-us/global-privacy-notice
About Danaher
At Danaher we bring together science, technology and operational capabilities to accelerate the real-life impact of tomorrow’s science and technology. We partner with customers across the globe to help them solve their most complex challenges, architecting solutions that bring the power of science to life. Our global teams are pioneering what’s next across Life Sciences, Diagnostics, Biotechnology and beyond. For more information, visit www.danaher.com
ZEISS is an internationally leading technology enterprise operating in the fields of optics and optoelectronics. In the previous fiscal year, the ZEISS Group generated annual revenue totaling almost 12 billion euros in its four segments Semiconductor Manufacturing Technology, Industrial Quality & Research, Medical Technology, and Consumer Markets (September 30, 2025).
For its customers, ZEISS develops, produces, and distributes highly innovative solutions for industrial metrology and quality assurance, microscopy solutions for the life sciences and materials research, and medical technology solutions for diagnostics and treatment in ophthalmology and microsurgery. The name ZEISS is also synonymous with the world's leading lithography optics, which are used by the chip industry to manufacture semiconductor components. There is global demand for trendsetting ZEISS brand products such as eyeglass lenses, camera lenses, and binoculars.
With a portfolio aligned with future growth areas like digitalization, healthcare, and Smart Production and a strong brand, ZEISS is shaping the future of technology and constantly advancing the world of optics and related fields with its solutions. The company's significant, sustainable investments in research and development lay the foundation for the success and continued expansion of ZEISS' technology and market leadership. ZEISS invests 15 percent of its revenue in research and development – this high level of expenditure has a long tradition at ZEISS and is also an investment in the future.
With over 46,600 employees, ZEISS is active globally in around 50 countries with more than 60 sales and service locations, around 40 research and development facilities, and 30 production facilities worldwide.
Learn more about ZEISS: www.zeiss.com/about
Data privacy: www.zeiss.com/data-protection
Imprint: www.zeiss.com/publisher
This is ZEISS's official LinkedIn account. It follows the ZEISS Netiquette: www.zeiss.com/netiquette